Filter By Category
Archives
Share on -
CEBRANOPADOL
Generic Name: CEBRANOPADOL
ABSTRACT -
Cebranopadol is a first-in-class analgesic that simultaneously activates the nociceptin/orphanin FQ peptide (NOP/ORL1) receptor and the classical mu, delta, and kappa opioid receptors. The dual mechanism is hypothesised to provide superior analgesia in nociceptive, neuropathic, and cancer pain while potentially offering a more favourable respiratory safety and abuse liability profile than pure mu-opioid agonists. Phase II/III trials evaluated it in chronic pain and cancer pain.
DOSAGE -
Oral tablet; 200–1000 µg once daily studied in Phase II/III trials for chronic pain; dose titrated based on analgesic response and tolerability.
SIDE EEFECTS -
- Nausea
- Dizziness
- Somnolence
- Constipation
- Vomiting
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Skin rash
- Urticaria
- Drug hypersensitivity
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- CNS depressants (benzodiazepines, alcohol, sedatives) — additive respiratory depression and sedation
- Strong CYP3A4 inhibitors increase cebranopadol exposure
- MAO inhibitors — potential serotonin syndrome risk
PREAUTONS–
- Assess abuse potential — schedule designation pending regulatory review
- Respiratory function monitoring especially in COPD or sleep apnoea
- Do not abruptly discontinue — taper to avoid withdrawal
- Pregnancy: neonatal opioid withdrawal syndrome risk
WARNINGS –
- Respiratory depression risk — titrate carefully, avoid in severe respiratory impairment
- Abuse and dependence potential — controlled substance status likely in most markets
- Neonatal opioid withdrawal syndrome if used during pregnancy
Share on -
. Developed by